Skip to content

Retrospective Study on the Efficacy of Platelet-Rich Plasma Injection in the Treatment of Patients with Chronic Pelvic Pain

Retrospective Study on the Efficacy of Platelet-Rich Plasma Injection in the Treatment of Patients with Chronic Pelvic Pain

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026000825
Enrollment
Unknown
Registered
2026-03-31
Start date
2025-09-26
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pelvic pain

Interventions

no:receive PRP injection therapy

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Meeting the diagnostic criteria for CPP/CPPS; Having received at least one session of pelvic floor PRP injection therapy in the Pain Management Department of our hospital from June 2022 to June 2024, with complete pre-treatment and post-treatment follow-up data (follow-up time points: pre-treatment, 2 hours post-treatment, 2 weeks post-treatment, and 1 month post-treatment); Visual Analogue Scale (VAS) score or Numerical Rating Scale (NRS) score more than 3 points.

Exclusion criteria

Exclusion criteria: Excluding patients with acute or organic lesions such as acute infections, malignant tumors, and ovarian cyst torsion; Pregnant women or virgins; CPP/CPPS patients with coagulation disorders (thrombocytopenia: platelet count less than100×10^9/L, prolonged prothrombin time more than 13 seconds), severe infections (e.g., sepsis), or autoimmune diseases (e.g., systemic lupus erythematosus, requiring long-term administration of immunosuppressants); CPP/CPPS patients with allergies to autologous blood components, or those who have used antiplatelet drugs (e.g., aspirin, clopidogrel) within the recent 3 months (with drug withdrawal duration 7 days ay least) or anticoagulant drugs (e.g., warfarin, low-molecular-weight heparin) (with drug withdrawal duration 14 days at least); CPP/CPPS patients receiving other pelvic floor intervention therapies during the same period.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale(VAS);

Secondary

MeasureTime frame
Pelvic floor biofeedback therapy unit;

Countries

China

Contacts

Public ContactJi Feng

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

medicjifeng@163.com15921485540

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026